TPST · Tempest Therapeutics, Inc.
$0.92
+0.01 (+1.58%)
At close · Aug 7
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“our need for additional capital to fund our planned programs and operations and to continue to operate as a going concern”View the 10-Q filed May 14, 2026
Market Cap
$13.36M
Shares
14.81M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.92
Open$0.91
Day$0.90–0.93
52W$0.84–12.23
Avg vol 30d155K
Short int318K · 2.1% float · 2.0d
Short vol44%
DataJan 2020–Aug 2026
Filing10-Q · May 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−68%
below
Price vs 50-day avg
−17%
below
RSI (14)
40
neutral
MACD trend
Positive
52-week position
1%
near low
Momentum
relative strength
1-month return
−6%
trailing
6-month return
−61%
trailing
YTD return
−68%
this year
Relative strength
−75%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Distributing
5 of 22 funds reported for Jun 30 · net -5 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.15% of float · ▲ +11.6% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
22 holders — mid 3-yr range
Squeeze score
48
elevated · 0–100
Fundamentals
Revenue growth
−55%
Y/Y
EPS growth
+68%
Y/Y
Free cash flow
$-26.8M
Balance sheet
$7.5M
net cash
Quant / Vol
risk profile
Volatility
101%
annualized · 1-yr
Max drawdown
−93%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−68%
Bearish
Price vs 50-day avg
−17%
Bearish
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Distributing
5 of 22 funds reported for Jun 30 · net -5 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.15% of float · ▲ +11.6% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
22 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 1%
52-wk high $12
vs 200-day avg -68%
vs 50-day avg -17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TPST
this stock
Tempest Therapeutics, Inc.
|
$13.36M | -68.1% | — | — | 2.1% |
|
ONC
BeOne Medicines Ltd.
|
$487.49B | +14.6% | +22179.2% | 749.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.68B | +9.4% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.49B | +1.9% | +20.8% | 19.1 | 3.4% |
|
ARGX
Argenx SE
|
$54.76B | +2.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TPST | +7.1% | -5.8% | -61.2% | +7.1% | -68.1% |
| SPY | +3.5% | +2.4% | +13.4% | +3.5% | +13.4% |
| vs SPY | +3.6% | -8.2% | -74.6% | +3.6% | -81.5% |